Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMRYEK)

• Drug Name: MPSK3169A Drug Info
• Synonyms: RG7652

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Phase 2	[1]
Metabolic disorder	5C50-5D2Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMMRYEK

Molecule-Related Drug Atlas

Drug(s) Targeting PCSK9 messenger RNA (PCSK9 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inclisiran	DMP3YTE	Familial hypercholesterolemia	5C80.00	Approved	[4]
AZD8233	DMBT2D2	Cardiovascular disease	BA00-BE2Z	Phase 2	[5]
BMS-PCSK9	DMRCMEK	Coronary artery disease	BA80	Preclinical	[6]
ALN-PCS	DMCJMOS	Hypercholesterolaemia	5C80.0	Preclinical	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PCSK9 messenger RNA (PCSK9 mRNA)	TTNIZ2B	PCSK9_HUMAN	Modulator	[3]

References

• [1] ClinicalTrials.gov (NCT01609140) A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease. U.S. National Institutes of Health.
• [2] GW24-e2907 ffects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study. Heart 2013;99:A153.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388).
• [4] FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 214012.
• [5] AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. Br J Clin Pharmacol. 2022 Nov;88(11):4839-4844.
• [6] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
• [7] Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).